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OBJECTIVES To evaluate clinical outcomes after the use of long coronary stents.
BACKGROUND The use of long slotted-tube stents has been recently approved in the U.S. to treat long lesions
or dissections. Procedural success and long-term outcomes of long versus short stents have not
been established.
METHODS We evaluated procedural success, major in-hospital complications, target lesion revascular-
ization and long-term (one year) clinical outcomes in 1,226 consecutive patients (1,259 native
coronary lesions) who underwent a single vessel intervention using a single long ($25 mm,
116 patients) or short (,20 mm, 1,110 patients) tubular-slotted stent.
RESULTS Patients treated with long stents had more diffuse (.10 mm length) lesions (63% vs. 28%,
p 5 0.001). The mean stent length was 28 6 5 mm versus 15 6 2 mm for long versus short
stent groups (p 5 0.001). Overall procedural success was similar in the long versus short stent
groups (96% vs. 98%, p 5 0.08). However, major in-hospital complications tended to occur
more frequently in patients treated with longer stents (3.4% vs. 1.0%, p 5 0.04). The rate of
periprocedural non-Q-wave myocardial infarction (MI) (creatine kinase-MB $5 times
normal) was notably higher after long stent implantation (23% vs. 11%, p 5 0.001). Target
lesion revascularization at one year was 14.5% vs. 13.8% (p 5 0.69), and target vessel
revascularization rate was 19.6% vs. 17.3% (p 5 0.41) in the long versus short stent group,
respectively. There was no difference in one year mortality (2.5% vs. 3.5%, p 5 0.49) or
Q-wave MI (2.7% vs. 1.2%, p 5 0.48), and the overall cardiac event-free survival was similar
for the two groups (81%).
CONCLUSIONS The use of single coronary long ($25 mm) versus short (,20 mm) stents is associated with:
1) somewhat increased major procedural complications, 2) significantly higher frequency of
periprocedural non-Q-wave MIs, and 3) equivalent repeat revascularization risk and cardiac
event-free survival out-of-hospital up to one year. (J Am Coll Cardiol 2000;35:612–8) ©
2000 by the American College of Cardiology
The treatment of atherosclerotic coronary plaques with
metallic slotted-tube stents has been shown to improve the
acute and long-term outcomes obtained by catheter-based
coronary interventions (1–4). Improved implantation tech-
niques using high-pressure balloon inflation and the addi-
tion of new antiplatelet pharmacotherapy enable stent im-
plantation without long-term anticoagulation, with very
low rates of periprocedural complications (5–7). Initia-
tory trials have shown favorable stent results compared
with balloon angioplasty in short lesions and relatively
large sized vessels (1,2). It is still unclear whether these
results can be generalized to longer lesions in diffuse
coronary disease (8). Data on the effectiveness of stent
treatment in diffuse disease scenarios are limited. Prior
studies have reported higher procedural complications
and stent thrombosis rates and more frequent late resten-
osis in patients treated with multiple stents placed in
diffuse lesions (9 –13). Recently, we showed that patients
with relatively large sized vessels treated with multiple
contiguous stents have favorable procedural results and
major cardiac event rates during follow-up (14). Accurate
positioning of multiple stents may become difficult,
however, with long overlapping stent segments or uncov-
ered gaps leading to inadequate results compared with
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single stent implantation in most otherwise reported
series.
Recently, with the availability of long stents in the U.S.,
we have compared the acute procedural and long-term (one
year) outcomes of patients with a single long ($25 mm)
versus short (,20 mm) slotted-tube stent implantation in
native coronary arteries.
METHODS
Patients and follow-up. The patient cohort includes a
consecutive series of 1,226 patients (1,259 native coronary
lesions) in the Cardiology Research Foundation Angio-
plasty Database treated with a single stent implanted in a
single native coronary artery between July 1, 1997, and July
1, 1998. Patients were divided into two groups: long stents
($25 mm) (n 5 116 patients) and a short (,20 mm) stent
group (n 5 1,110 patients). All indications for stent use
(elective use to optimize angiographic results and reduce late
restenosis, provisional use to treat suboptimal primary de-
vice result or urgent use to treat abrupt or threatened vessel
closure) are included in this study. Baseline clinical demo-
graphics and in-hospital complications were confirmed by
independent hospital chart review.
All patients underwent pre- and post-intervention, 12-
lead electrocardiogram to detect procedural related ischemic
changes or the appearance of a new pathologic Q-wave on
the surface ECG. Blood samples were routinely acquired
from all patients after the procedure for creatine kinase
(CK)-MB enzyme at 8, 16 and 24 h (normal values 0 to 4
ng/ml). The diagnosis of non-Q-wave myocardial infarction
(MI) was based on CK-MB elevation $5 times normal
values in the absence of new pathologic Q-waves on
post-intervention electrocardiograms. Periprocedural
CK-MB elevation is also reported as three times normal
cut-off. Out-of-hospital clinical outcomes up to eight
months were obtained by serial telephone interviews by
research nurses and late clinical events (death, Q-wave MI),
target lesion revascularization (TLR), target vessel revascu-
larization (TVR) or any cardiac event (death, Q-wave MI,
TLR) was adjudicated and corroborated by accompanying
source documentation.
Stent techniques. After the initial balloon angioplasty or
ablative procedure, coronary stents were implanted over
0.014 in. extra-support guidewire. All stents used during the
study period were included in the current analysis. Adjunct
balloon inflation (usually ;16 atmospheres) was added after
initial stent deployment in all cases. Optimal stent implan-
tation was carefully monitored using an iterative technique
with intravascular ultrasound (IVUS) monitoring in the
majority of cases. The pre- and post-stent anticoagulation
regimens included aspirin (325 mg daily) and ticlopidine
(250 mg twice daily) for one month. Patients with inter-
vention in more than one vessel or more than a single stent
were excluded from analysis.
Quantitative angiographic analysis. Five hundred ninety-
six lesions were available for complete quantitative and
qualitative angiographic analysis. Standard morphologic
criteria were used for the identification of lesion location,
length, eccentricity, calcification and ulceration. Quantita-
tive angiographic analysis was performed using selected
end-diastolic frames demonstrating the stenosis in its most
severe projection. Using the contrast-filled guiding catheter
as the calibration standard, proximal and distal references
(within 5 mm of lesion margins) were measured and lesion
minimal lumen diameters and percent diameter stenosis
were determined before and after intervention.
Statistics. Continuous variables are presented as mean 6 1
standard deviation. Categorical data are presented as per-
cent frequency and compared between groups using chi-
square statistics. Survival curves were calculated and dis-
played using the SAS LIFETEST (SAS Institute, Cary,
North Carolina) procedure and Log-Rank statistics were
used for testing of survival homogeneity between the two
groups. Wilcoxon statistics were used for survival compar-
ison between groups (long versus short stents). Mean values
were compared using the unpaired Student t test. A p value
,0.05 was accepted as statistically significant.
RESULTS
Baseline demographics. Table 1 lists the baseline charac-
teristics of all treated patients, distinguished according to
long versus short stents. Patients treated with long stents on
the average were younger and suffered more often from
hypertension and previous MI but had sustained fewer prior
coronary angioplasty procedures. Otherwise, the demo-
graphics were similar between these two groups.
Procedural data. Before stent deployment, atheroablation
was performed in 17% and 16% of the patients in the two
groups (Table 2). Overall, the types of stents used were
different between groups with the majority (80%) of patients
in the short stent group treated with the Palmaz-Schatz
stent (Cordis Corp., Warren, New Jersey) and the long stent
group treated with either the multilink (33%), Micro-II/
GFX (Applied Vascular Engineering Inc., Santa Rosa,
California) (32%) or the NIR stent (13%). The mean stent
Abbreviations and Acronyms
CK 5 creatinine kinase
IVUS 5 intravascular ultrasound
MB 5 myocardial band
MI 5 myocardial infarction
OR 5 odds ratio
QCA 5 quantitative coronary angiography
TIMI 5 thrombolysis in myocardial infarction
TLR 5 target lesion revascularization
TVR 5 target vessel revascularization
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length (long vs. short) was 28 6 5 mm versus 15 6 2 mm
(p 5 0.001). The number of provisional/planned versus
urgent stenting was similar in the two groups (97% vs. 96%
and 3% vs. 4%; p 5 NS). Importantly, the periprocedural
use of abciximab was significantly more frequent in patients
treated with long versus short stents (14 vs. 3.9%, p 5
0.001).
Lesion characteristics. Table 3 lists the lesion location data
for all 1,259 native coronary lesions and full qualitative and
quantitative measurements obtained in 535 lesions. The lesions
were similarly distributed among the coronary arteries between
groups but short stents were more frequently implanted in the
ostial location. Longer stents were more often implanted in
longer (.10 mm) lesions or in those with preprocedural
Thrombolysis in Myocardial Infarction (TIMI) 0/1 flow but
less often in restenotic or calcified lesions. Angiographic
complications (dissections, abrupt closure or no reflow) were
similarly observed in both groups. By quantitative angiography,
the average proximal reference diameter was similar between
groups, but the distal reference was smaller for the long stent
group (2.7 6 0.8 vs. 2.9 6 0.6 mm, p 5 0.01) as the vessel
tapered to a longer distance in this group. Postprocedural
lesion measurements were different; the final poststent minimal
lumen diameter was smaller (2.5 6 0.7 mm vs. 2.8 6 0.6 mm,
p 5 0.001), and accordingly, the final stent diameter stenosis
was higher (19 6 13% vs. 9 6 16%, p 5 0.001), signifying
more residual stenosis immediately after longer stenting (Table
3).
Procedural results. Overall procedural success was similar
in the long versus short stent groups (96% vs. 98%, p 5
0.08) (Table 4). However, major in-hospital complications
tended to occur more frequently in patients treated with
longer stents (3.4% vs. 1.0%, p 5 0.04). The rate of
periprocedural non-Q-wave MI (CK-MB $ 5 times nor-
mal) was notably higher after longer stent implantation
(23% vs. 11%, p 5 0.001). The length of hospitalization,
however, was similar for both groups (3.2 6 2.7 vs. 3.8 6
4.5 days for long vs. short stents, respectively, p 5 0.08).
The rates of in-hospital repeat target vessel angioplasty and
stent thrombosis were similar for the two groups.
Long-term outcomes. Clinical follow-up at one year was
available in 102 of 116 patients (88%) treated with long
stents and in 1,024 of 1,110 patients (92%) treated with
shorter stents. During follow-up, there was no difference in
mortality between groups (2.5% for long versus 3.5% for
short stents, p 5 0.49) (Table 4). The rate of Q-wave MI
was also similar for long stent group versus short stenting
(2.7% vs. 1.2%, p 5 0.18). Overall TLR at one year was
14.5% for long stents versus 13.8% in short stent group (p 5
0.69, Fig. 1A). Similarly, TVR was higher but similar for
both groups (p 5 0.41). Likewise, actuarial event-free
survival curves for any event during one-year follow-up
(death, Q-wave MI, TLR) was similar for both group
(81.3% for long stents versus 81.5% for short stents, p 5
0.44, Fig. 1B).
Multivariate analysis. Logistic regression analysis was
used to identify independent predictors of any cardiac event
Table 1. Baseline Characteristics of the Study Population
Vessels Treated
(Patients)
Long
(N 5 116)
Short
(N 5 1110)
p
Value
Mean age (yrs) 63 6 12 62 6 12 0.40
Male gender (%) 60 69 0.04
Unstable angina (%) 71 67 0.36
Hypertension (%) 67 58 0.06
Diabetes mellitus (%) 32 30 0.75
Hypercholesterolemia (%) 68 67 0.86
Prior MI (%) 62 49 0.007
Prior CABG (%) 15 19 0.21
Prior angioplasty (%) 32 42 0.05
LVEF (%) 48 6 14 47 6 12 0.77
CABG 5 coronary artery bypass grafting; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction.
Table 2. Interventional Procedures
Vessels (Lesions)
Long
(N 5 117)
Short
(N 5 1142)
p
Value
Procedure Type (pre-stent)
Balloon alone (%) 83 84 0.73
Atheroablation (%) 17 16 0.73
IVUS performed (%) 84 85 0.79
Type of Stent
Palmaz-Schatz/Crown (%) 7 80 0.001
Multilink-Duette (%) 33 9 0.001
NIR (%) 13 5 0.001
Micro-II/GFX (%) 32 9 0.001
Wallstent (%) 9 0 0.001
Others (%) 6 9 0.72
Mean Stent Length (mm) 28 6 5 15 6 2 0.001
Abciximab Used (%) 14 3.9 0.001
IVUS 5 intravascular ultrasound.
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(death, Q-wave MI, TLR) or TLR alone following a single
vessel/lesion stenting among the treated patients (Table 5).
Variables included in the model were unstable angina, age,
gender, history of angioplasty, diabetes mellitus, use of abcix-
imab, proximal reference vessel diameter, distal reference vessel
diameter, final percent diameter stenosis, stent length, stent
type, ostial location, and lesion length. Diabetes (odds ratio
[OR] 5 1.9), history of angioplasty (1.9), proximal reference
diameter (0.68) and unstable angina (OR 5 1.6) were inde-
pendent predictors of any adverse cardiac event during follow-
up. History of angioplasty (OR 5 2.1) and proximal reference
vessel diameter (OR 5 0.57) were the only predictors for TLR.
Neither stent length nor lesion length predicted subsequent
adverse cardiac events from the time of hospital discharge to
one-year follow-up.
Stent to artery ratio. Stent to lesion length ratio (as
determined by the known stent length and the measured
lesion length by QCA) was plotted against TLR and TVR
at follow-up. According to this analysis, there were no
significant differences in rates of TLR or TVR between
groups distinguished on the basis of stent to lesion length
ratio, (Fig. 2).
DISCUSSION
The treatment of diffuse coronary artery disease has been
traditionally associated with disappointing acute and long-
term results in most reported “conventional” balloon angio-
plasty and new-devices series, with increased risk for acute
complications and restenosis (15–18). In the stent era, two
main approaches to stenting of diffuse lesions have been
advocated: “spot” stenting of only severe stenosis or full
lesion coverage with the goal of anchoring stents into
“normal” reference segments (19). Until long stents became
available, full coverage of diffuse lesions or long dissection
could have been achieved only by the use of multiple
overlapping stents (9–13) or long self-expandable stents
(20,21). Recent experiences suggested that such strategy
advocated to treat long lesions is feasible, with relatively low
procedural complications but with relatively high restenosis
rate, unless used to scaffold diffuse lesions in large
($3.25 mm) sized vessels (14). The various problems that
were observed in other studies with multiple stenting in the
same vessel included increased risk of subacute thrombosis
(11), restenosis (12,13) and technical difficulty in deploying
multiple stents with increased catheterization time, dye
Table 3. Qualitative and Quantitative Characteristics of Stented Lesions
Vessels (Lesions)
Long
(N 5 117)
Short
(N 5 1142)
p
Value
Target Vessel
RCA (%) 36 34 0.75
LAD (%) 38 36 0.80
LCx (%) 25 25 1.00
Lt Main 0.9 4.4 0.07
Ostial (%) 4.3 10 0.036
Proximal (%) 38 40 0.70
Lesion Characteristics (N 5 92) (N 5 504)
Restenotic (%) 14 24 0.01
Calcium (%) 18 31 0.07
Length (mm) 13 6 8 9 6 6 0.001
Length .10 mm (%) 63 28 0.001
Ulceration (%) 4.8 8.6 0.19
Eccentricity (%) 40 48 0.19
Type B2/C (%) 62 44 0.35
TIMI 0 or 1 12 3.2 0.01
Procedural Complications
Dissection $ type C (%) 1.0 0.9 0.96
Abrupt closure (%) 0.9 0.4 0.34
No reflow (%) 1.1 0 0.46
Quantitative Measurements
Proximal reference diameter (mm) 3.2 6 0.6 3.1 6 0.6 0.33
Distal reference diameter (mm) 2.7 6 0.8 2.9 6 0.6 0.01
Preprocedure (mm) 1.1 6 0.5 1.0 6 0.5 0.28
Final poststent (mm) 2.5 6 0.7 2.8 6 0.6 0.001
Lesion % diameter stenosis
Preprocedure (%) 62 6 13 67 6 15 0.01
Final poststent (%) 19 6 13 9 6 16 0.001
LCx 5 left circumflex; Lt Main 5 left main; RCA 5 right coronary artery; TIMI 5 thrombolysis in myocardial infarction.
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volume and radiation exposure (22). Moreover, the greater
metal density and repeated stent on stent trauma with
overlapping stents was proposed to impair vessel wall
integrity causing a higher degree of vascular injury and
promoting more neointimal proliferation (23,24).
The availability of long stents in the U.S. with improved
flexibility, trackablity and scaffolding properties has pro-
vided us with the opportunity to compare the acute proce-
dural and long-term results following treatment of coronary
narrowing using longer slotted-tube stents in native coro-
nary arteries. Several studies have implicated stent length or
the number of stents implanted as contributing factors to
restenosis in addition to intrinsic lesion characteristics that
predispose neointimal formation (23–25). Our study’s main
finding is that, unlike previous reports, the use of a single
coronary long ($25 mm) versus short (,20 mm) stent is
associated with: 1) somewhat increased major procedural
complications, 2) significantly higher frequency of peripro-
cedural non-Q-wave MIs or any CK-MB elevation, and 3)
equivalent repeat revascularization risk and event-free sur-
vival out-of-hospital up to one year. According to our
experience, the periprocedural use of abciximab was signif-
icantly more prevalent in patients treated with long versus
short stents. This may partially account for improved
Figure 1. (A) Actuarial event-free survival curves for target lesion
revascularization (TLR), (B) or any adverse event (death, Q-wave
MI or TLR) for one year following long ($25 mm) versus short
(,20 mm) slotted-tube single vessel stenting.
Table 4. In-Hospital Procedural Results and Clinical Outcomes at 12 Months Follow-up
Vessels (Patients)
Long
(N 5 116)
Short
(N 5 1,110)
p
Value
In-Hospital
Procedural success (%) 96 98 0.08
Major Hospital Complications
Death (%) 0.9 0.4 0.39
Q-wave infarction (%) 1.7 0.2 0.02
Emergent coronary bypass (%) 0.9 0.4 0.55
Combined (%) 3.4 1.0 0.04
Non Q-wave MI (%) 23 11 0.001
CK-MB $3 normal (%) 30 14 0.001
Stent thrombosis (%) 0.9 0.7 0.57
Repeat angiopasty (%) 1.7 1.0 0.34
One-Year Follow-up
Death (%) 2.5 3.5 0.49
Q-wave infarction (%) 2.7 1.2 0.18
TLR (%) 14.5 13.8 0.69
TVR (%) 19.6 17.3 0.41
Cardiac event-free survival (%) 81.3 81.5 0.44
CK 5 creatine kinase; TLR 5 target lesion revascularization; TVR 5 target vessel revascularization.
Table 5. Independent Predictors of Any Cardiac Event and
TLR During One-Year Follow-up Period
Predictive Variables
Odds
Ratio
95%
Confidence
Limits
p
Value
Any Cardiac Event
Diabetes mellitus 1.9 1.2–3.0 0.003
History of angioplasty 1.9 1.2–2.9 0.004
Proximal reference vessel
diameter
0.68 0.47–0.98 0.04
Unstable angina 1.6 1.0–2.3 0.05
TLR
History of angioplasty 2.1 1.3–3.5 0.002
Proximal reference vessel
diameter
0.57 0.39–0.83 0.003
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procedural and long-term results obtained by longer stents in
our patient cohort. However, the overall use of abciximab has
been relatively low in both groups at the time of this study.
Importantly, the stent to lesion length ratio has not been
shown to be a major determinant of subsequent TLR or TVR
in our experience. It is also notable that the proximal reference
vessel diameter (but not the distal one) was among the
strongest predictors of TLR according to a multivariate model,
implying that the vessel size in its proximal lesion inlet plays an
important role in achieving favorable results in diffuse disease
scenarios requiring long stents. Interestingly, stent length was
not predictive of TLR in our model. This finding is in
accordance with our previous observation in single and mul-
tivessel stenting (14,26).
In this study, there was a notably higher frequency (23%)
of procedural related non-Q-wave MI in patients treated
with long stents. Such higher prevalence of periprocedural
CK-MB elevation may reflect a more complex clinical and
anatomic milieu in patients treated with longer lesions such
as diffuse disease, thrombus containing lesions, more exten-
sive dissections, chronic total occlusions and side branch
vessel occlusion. In this respect, it was recently found that
pre-intervention lesion characteristics and especially the
measured amount of plaque at the lesion site are the major
determinants of CK-MB elevation after coronary stenting
(27). Despite other reports indicating a strong association
between periprocedural CK-MB elevations and late adverse
cardiac events (28–30), thus far, our preliminary out-of-
hospital experience with long stents did not indicate higher
mortality or Q-wave MI rates compared with shorter stents.
However, it should be noted that if “major” CK-MB
elevation had to be accounted for by major adverse cardiac
events, the overall event rates would have been much higher
in the long stent group in our study.
Our results corroborate with previous reports by showing
that stenting of long lesions using the “new generation” long
stents can be accomplished with high procedural success and
relatively low complications rates. Rozenman et al. (31) have
treated 57 patients with 67 long (.30 mm) various types of
stents. Procedural success has been obtained in all but one
patient. Beyar et al. (32) have reported the results obtained
by using the long version of the BeStent (Medtronic Inc.,
Minneapolis, Minnesota) to treat diffuse lesions. Procedural
success was high and achieved in 97% of patients, but overall
restenosis rate was higher in patients with longer lesions
who were treated with longer (mostly 25 mm) stents.
Kobayashi et al., (33) using a 32 mm NIR stent have
reported angiographic restenosis rates of 51% compared
with 13.3% in patients treated with 16 mm NIR stents.
Nevertheless, those patients also differed in reference vessel
size, with bigger reference diameter found in the shorter
stent group, probably accounting for the difference in
restenosis rate. More recently, LeBreton et al. (34) have
reported their experience with the use of long (32 mm) NIR
stents in 187 patients enrolled in a large multicenter French
registry. Angiographic success has been obtained in 99% of
treated lesions. At follow-up (mean seven months), stent
thrombosis occurred in 0.5%, death and MI occurred in 3%
and 0.6%, respectively, and TLR rate was only 6%. Overall,
cardiac event-free survival has been 86% and very similar to
our own experience. Finally, a nonrandomized registry
comparing the long (39 mm) AVE Micro II stent with the
Palmaz-Schatz (15 mm) stent found similar procedural
results and a similar TLR rate (9.2% vs. 8.1%, p 5 NS)
despite longer lesions on average (23 vs. 12 mm) and more
“high risk” baseline demographics among patients treated
with the longer stent (35).
Two IVUS studies from our laboratory may explain the
observed findings in which clinical restenosis rates have not
been excessive with longer stent implantation or higher
stent-to-lesion length coverage ratio. Hong et al. (36) have
measured in vivo stent length by IVUS and found that when
stent length has been adjusted to IVUS measured postint-
ervention lumen area, the increase in length did not impact
TLR. Moreover, it was found that increasing the stent to
lesion length ratio while optimizing full lesion coverage
actually decreased the TLR rate (37). Those observations
help explain our study findings in which relatively low TLR
rates were observed among patients treated with single long
stents, and they may indicate the full lesion coverage
approach for diffuse lesions.
Study limitations. Since this study was a retrospective
analysis, it is unknown whether the use of a different
therapeutic strategy for diffuse disease (e.g., “spots” stenting,
more use of atheroablation devices before stenting) would
result in comparable procedural or late outcomes obtained
by long stenting. Moreover, the significantly increased use
of abciximab with longer stents is another important factor
that may have had a beneficial impact on the results
obtained by the use of longer stents. However, the overall
use of abciximab in this study was relatively low. Impor-
tantly, the comparison of long versus short stents is neces-
sarily confounded by significant differences in lesion char-
acteristics between the two groups, with the short stent
group having more ostial, restenotic and calified lesions but
Figure 2. Stent-to-lesion length ratio plotted against target lesion
(TLR) and target vessel (TVR) revascularization rates.
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less total occlusions and prior MI. It is also possible that, if
long stents were to be implanted in smaller vessels, the acute
and especially long-term clinical outcomes would be less
favorable compared with short stents. Also, it is possible
that the higher incidence of total occlusions with TIMI 0/1
flow in the long stent group might have diminished the
capacity for revascularization in the event that restenosis or
reocclusion occurred, masking additional restenosis in the
longer stent group. The lack of angiographic follow-up with
an accurate assessment of restenosis is another potential
limitation of our study. This is also the reason we could not
assess retenosis patterns (focal vs. diffuse) in each group. In
addition, the power of the multivariate analysis was limited
by the relatively small number of lesions with quantitative
angiographic assessment compared with the clinical data.
Finally, our study did not compare different stent designs to
determine which may have properties better suited for the
treatment of long lesions.
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